(OHI) Omega Healthcare Investors - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6819361006
Stock: Healthcare Facilities, Real Estate, Investments
Total Rating 58
Risk 56
Buy Signal -0.05
| Risk 5d forecast | |
|---|---|
| Volatility | 19.7% |
| Relative Tail Risk | -3.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.63 |
| Alpha | 32.65 |
| Character TTM | |
|---|---|
| Beta | -0.084 |
| Beta Downside | -0.157 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.47% |
| CAGR/Max DD | 1.95 |
EPS (Earnings per Share)
Revenue
Description: OHI Omega Healthcare Investors March 05, 2026
Omega Healthcare Investors Inc. (OHI) operates as a Real Estate Investment Trust (REIT) specializing in the long-term healthcare sector. The company provides financing and capital for skilled nursing and assisted living facilities in the US and UK.
As of a recent reporting period, OHIs portfolio comprised over 1,000 operating facilities across 42 US states, the District of Columbia, and the UK/Jersey, managed by numerous operators. Healthcare REITs typically lease properties to healthcare providers under long-term agreements.
OHI focuses on identifying long-term investments in quality healthcare properties with strong operators, aiming for favorable risk/reward profiles. The long-term healthcare sector faces evolving regulatory and demographic challenges. For more detailed financial analysis, ValueRay offers comprehensive data.
Headlines to watch out for
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 590.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: 122.7% < 20% (prev 219.6%; Δ -96.87% < -1%) |
| CFO/TA 0.09 > 3% & CFO 879.7m > Net Income 590.1m |
| Net Debt (4.23b) to EBITDA (1.17b): 3.62 < 3 |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (313.2m) vs 12m ago 8.97% < -2% |
| Gross Margin: 84.91% > 18% (prev 0.99%; Δ 8393 % > 0.5%) |
| Asset Turnover: 11.96% > 50% (prev 10.62%; Δ 1.34% > 0%) |
| Interest Coverage Ratio: 3.92 > 6 (EBITDA TTM 1.17b / Interest Expense TTM 215.1m) |
Altman Z'' -0.45
| A: 0.15 (Total Current Assets 2.06b - Total Current Liabilities 594.5m) / Total Assets 10.05b |
| B: -0.36 (Retained Earnings -3.62b / Total Assets 10.05b) |
| C: 0.08 (EBIT TTM 842.4m / Avg Total Assets 9.97b) |
| D: -0.76 (Book Value of Equity -3.51b / Total Liabilities 4.61b) |
| Altman-Z'' Score: -0.45 = B |
Beneish M -2.70
| DSRI: 0.87 (Receivables 2.00b/2.03b, Revenue 1.19b/1.05b) |
| GMI: 1.16 (GM 84.91% / 98.62%) |
| AQI: 1.38 (AQ_t 0.13 / AQ_t-1 0.09) |
| SGI: 1.13 (Revenue 1.19b / 1.05b) |
| TATA: -0.03 (NI 590.1m - CFO 879.7m) / TA 10.05b) |
| Beneish M-Score: -2.70 (Cap -4..+1) = A |
What is the price of OHI shares?
As of March 08, 2026, the stock is trading at USD 47.69 with a total of 2,139,629 shares traded.
Over the past week, the price has changed by -1.20%, over one month by +6.90%, over three months by +5.95% and over the past year by +41.57%.
Over the past week, the price has changed by -1.20%, over one month by +6.90%, over three months by +5.95% and over the past year by +41.57%.
Is OHI a buy, sell or hold?
Omega Healthcare Investors has received a consensus analysts rating of 3.69.
Therefor, it is recommend to hold OHI.
- StrongBuy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.1 | 2.9% |
| Analysts Target Price | 49.1 | 2.9% |
OHI Fundamental Data Overview March 05, 2026
P/E Trailing = 24.4639
P/E Forward = 10.1317
P/S = 12.1145
P/B = 2.7445
P/EG = 1.13
Revenue TTM = 1.19b USD
EBIT TTM = 842.4m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 4.26b USD (from longTermDebt, last quarter)
Short Term Debt = 242.0m USD (from shortTermDebt, last quarter)
Debt = 4.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.23b USD (from netDebt column, last quarter)
Enterprise Value = 18.65b USD (14.42b + Debt 4.26b - CCE 27.0m)
Interest Coverage Ratio = 3.92 (Ebit TTM 842.4m / Interest Expense TTM 215.1m)
EV/FCF = 21.69x (Enterprise Value 18.65b / FCF TTM 859.8m)
FCF Yield = 4.61% (FCF TTM 859.8m / Enterprise Value 18.65b)
FCF Margin = 72.09% (FCF TTM 859.8m / Revenue TTM 1.19b)
Net Margin = 49.47% (Net Income TTM 590.1m / Revenue TTM 1.19b)
Gross Margin = 84.91% ((Revenue TTM 1.19b - Cost of Revenue TTM 179.9m) / Revenue TTM)
Gross Margin QoQ = 47.22% (prev none%)
Tobins Q-Ratio = 1.86 (Enterprise Value 18.65b / Total Assets 10.05b)
Interest Expense / Debt = 1.22% (Interest Expense 51.8m / Debt 4.26b)
Taxrate = 1.22% (2.13m / 174.1m)
NOPAT = 832.1m (EBIT 842.4m * (1 - 1.22%))
Current Ratio = 3.46 (Total Current Assets 2.06b / Total Current Liabilities 594.5m)
Debt / Equity = 0.82 (Debt 4.26b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = 3.62 (Net Debt 4.23b / EBITDA 1.17b)
Debt / FCF = 4.92 (Net Debt 4.23b / FCF TTM 859.8m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.92% (Net Income 590.1m / Total Assets 10.05b)
RoE = 11.83% (Net Income TTM 590.1m / Total Stockholder Equity 4.99b)
RoCE = 9.11% (EBIT 842.4m / Capital Employed (Equity 4.99b + L.T.Debt 4.26b))
RoIC = 8.61% (NOPAT 832.1m / Invested Capital 9.66b)
WACC = 4.60% (E(14.42b)/V(18.67b) * Re(5.60%) + D(4.26b)/V(18.67b) * Rd(1.22%) * (1-Tc(0.01)))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 10.49%
[DCF] Terminal Value 86.91% ; FCFF base≈801.0m ; Y1≈850.5m ; Y5≈1.02b
[DCF] Fair Price = 87.48 (EV 30.09b - Net Debt 4.23b = Equity 25.86b / Shares 295.6m; r=5.90% [WACC]; 5y FCF grow 6.85% → 2.90% )
EPS Correlation: 31.00 | EPS CAGR: -9.20% | SUE: 0.65 | # QB: 0
Revenue Correlation: 64.92 | Revenue CAGR: 7.04% | SUE: 3.38 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.54 | Chg7d=+0.068 | Chg30d=+0.068 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.039 | Chg30d=+0.107 | Revisions Net=+1 | Growth EPS=+0.6% | Growth Revenue=+14.9%
EPS next Year (2027-12-31): EPS=2.10 | Chg7d=-0.020 | Chg30d=+0.108 | Revisions Net=+1 | Growth EPS=+2.8% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +18.3% (Analyst 22.1% - Implied 3.9%)
P/E Forward = 10.1317
P/S = 12.1145
P/B = 2.7445
P/EG = 1.13
Revenue TTM = 1.19b USD
EBIT TTM = 842.4m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 4.26b USD (from longTermDebt, last quarter)
Short Term Debt = 242.0m USD (from shortTermDebt, last quarter)
Debt = 4.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.23b USD (from netDebt column, last quarter)
Enterprise Value = 18.65b USD (14.42b + Debt 4.26b - CCE 27.0m)
Interest Coverage Ratio = 3.92 (Ebit TTM 842.4m / Interest Expense TTM 215.1m)
EV/FCF = 21.69x (Enterprise Value 18.65b / FCF TTM 859.8m)
FCF Yield = 4.61% (FCF TTM 859.8m / Enterprise Value 18.65b)
FCF Margin = 72.09% (FCF TTM 859.8m / Revenue TTM 1.19b)
Net Margin = 49.47% (Net Income TTM 590.1m / Revenue TTM 1.19b)
Gross Margin = 84.91% ((Revenue TTM 1.19b - Cost of Revenue TTM 179.9m) / Revenue TTM)
Gross Margin QoQ = 47.22% (prev none%)
Tobins Q-Ratio = 1.86 (Enterprise Value 18.65b / Total Assets 10.05b)
Interest Expense / Debt = 1.22% (Interest Expense 51.8m / Debt 4.26b)
Taxrate = 1.22% (2.13m / 174.1m)
NOPAT = 832.1m (EBIT 842.4m * (1 - 1.22%))
Current Ratio = 3.46 (Total Current Assets 2.06b / Total Current Liabilities 594.5m)
Debt / Equity = 0.82 (Debt 4.26b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = 3.62 (Net Debt 4.23b / EBITDA 1.17b)
Debt / FCF = 4.92 (Net Debt 4.23b / FCF TTM 859.8m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.92% (Net Income 590.1m / Total Assets 10.05b)
RoE = 11.83% (Net Income TTM 590.1m / Total Stockholder Equity 4.99b)
RoCE = 9.11% (EBIT 842.4m / Capital Employed (Equity 4.99b + L.T.Debt 4.26b))
RoIC = 8.61% (NOPAT 832.1m / Invested Capital 9.66b)
WACC = 4.60% (E(14.42b)/V(18.67b) * Re(5.60%) + D(4.26b)/V(18.67b) * Rd(1.22%) * (1-Tc(0.01)))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 10.49%
[DCF] Terminal Value 86.91% ; FCFF base≈801.0m ; Y1≈850.5m ; Y5≈1.02b
[DCF] Fair Price = 87.48 (EV 30.09b - Net Debt 4.23b = Equity 25.86b / Shares 295.6m; r=5.90% [WACC]; 5y FCF grow 6.85% → 2.90% )
EPS Correlation: 31.00 | EPS CAGR: -9.20% | SUE: 0.65 | # QB: 0
Revenue Correlation: 64.92 | Revenue CAGR: 7.04% | SUE: 3.38 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.54 | Chg7d=+0.068 | Chg30d=+0.068 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.039 | Chg30d=+0.107 | Revisions Net=+1 | Growth EPS=+0.6% | Growth Revenue=+14.9%
EPS next Year (2027-12-31): EPS=2.10 | Chg7d=-0.020 | Chg30d=+0.108 | Revisions Net=+1 | Growth EPS=+2.8% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +18.3% (Analyst 22.1% - Implied 3.9%)